Abstract
The role of elevated triglyceride (TG) levels in the pathogenesis of atherosclerosis is controversial. Some studies suggest that TG might play a direct role in the development of vascular disease. Elevated TG levels are also associated with other vascular risk factors and may therefore represent an indirect marker of a high risk state. Another issue is that laboratory measurements of TG levels frequently show a substantial variability. Accumulating epidemiological data show that there is an independent association of TG levels with vascular risk. Some interventional studies also suggested that lowering TG levels might prevent vascular events. It appears that TG might be more important as therapeutic targets against a background of optimal low density lipoprotein cholesterol (LDL-C) levels. In this context, statins that are more effective in reducing TG levels, fibrates that can safely be combined with statins or fixed fibrate and statin combinations, as well as new, better tolerated nicotinic acid formulations might prove to be particularly beneficial.
Keywords: Triglyceride, statins, fibrates, nicotinic acid, cardiovascular disease, vascular risk
Current Drug Targets
Title: Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies
Volume: 10 Issue: 4
Author(s): Konstantinos Tziomalos, Vasilios G. Athyros, Asterios Karagiannis, Genovefa D. Kolovou and Dimitri P. Mikhailidis
Affiliation:
Keywords: Triglyceride, statins, fibrates, nicotinic acid, cardiovascular disease, vascular risk
Abstract: The role of elevated triglyceride (TG) levels in the pathogenesis of atherosclerosis is controversial. Some studies suggest that TG might play a direct role in the development of vascular disease. Elevated TG levels are also associated with other vascular risk factors and may therefore represent an indirect marker of a high risk state. Another issue is that laboratory measurements of TG levels frequently show a substantial variability. Accumulating epidemiological data show that there is an independent association of TG levels with vascular risk. Some interventional studies also suggested that lowering TG levels might prevent vascular events. It appears that TG might be more important as therapeutic targets against a background of optimal low density lipoprotein cholesterol (LDL-C) levels. In this context, statins that are more effective in reducing TG levels, fibrates that can safely be combined with statins or fixed fibrate and statin combinations, as well as new, better tolerated nicotinic acid formulations might prove to be particularly beneficial.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, Athyros G. Vasilios, Karagiannis Asterios, Kolovou D. Genovefa and Mikhailidis P. Dimitri, Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies, Current Drug Targets 2009; 10 (4) . https://dx.doi.org/10.2174/138945009787846425
DOI https://dx.doi.org/10.2174/138945009787846425 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine Treatment of Fabry Disease: Current and Emerging Strategies
Current Pharmaceutical Biotechnology Uric Acid and the Kidney: Urate Transport, Stone Disease and Progressive Renal Failure
Current Pharmaceutical Design Pharmacogenomics in the Intensive Care Unit: Focus on Potential Implications for Clinical Practice
Recent Patents on Biotechnology Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Methods for Identifying Cardiovascular Agents: A Review
Recent Patents on Cardiovascular Drug Discovery MicroRNA Expression in Coronary Artery Disease
MicroRNA Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews Efficient Expression and Purification of Recombinant Therapeutic Protein Candidates, Human Midkine and Pleiotrophin
Current Pharmaceutical Biotechnology Heart Failure Pharmacotherapy: Differences Between Adult and Paediatric Patients
Current Medicinal Chemistry Motion Analysis of the Carotid Artery Wall and Plaque Using B-Mode Ultrasound
Vascular Disease Prevention (Discontinued) Phytochemical Genistein in the Regulation of Vascular Function: New Insights
Current Medicinal Chemistry Social Media as a Means to Disseminate and Advocate Cardiovascular Research: Why, How, and Best Practices
Current Cardiology Reviews Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
Current Pharmaceutical Design Schizophrenia: Causes and Treatments
Current Pharmaceutical Design Hypothyroidism and Cardiovascular Disease: Factors, Mechanism and Future Perspectives
Current Medicinal Chemistry Myocardial Perfusion SPECT Imaging in Patients after Coronary Revascularization
Vascular Disease Prevention (Discontinued) Prader-Willi Syndrome: Clinical Genetics and Diagnostic Aspects with Treatment Approaches
Current Pediatric Reviews Central Blood Pressure and End-organ Damage
Current Hypertension Reviews Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Current Pharmaceutical Design